Clinical trials: H Pylori Eradication
Helicobacter Pylori Infection, Gastrointestinal Dysbiosis
Bacillus Probiotics With Bismuth Quadruple Therapy for Helicobacter Pylori Infection
Helicobacter pylori (H. pylori) is a very common gastrointestinal disease that colonises the human gastric mucosa and is a primary risk factor for chronic gastritis, peptic ulcer disease, and gastric cancer.
- Conditions
- Helicobacter Pylori Infection, Gastrointestinal Dysbiosis, Antibiotic-associated Adverse Events
- Trial name
- NCT07827170
- Testing
- RO water, LiveSpo CLAUSY, LiveSpo DIA30
- Where
- Vietnam
- Volunteers
- 336 people
- Sponsor
- Anabio R&D
Lymphoma, Lymphoma, Non-Hodgkin
Helicobacter - Lymphoma - Radiation Part I: Eradication, Part II: Radiation
The first objective of this study is to confirm the results of complete remission of low-grade gastric MALT lymphoma stage IE \& II1E after H. pylori eradication on a larger number of patients (HELYX Part I).
- Trial name
- NCT00154440
- Testing
- proton pump inhibitor, clarithromycin, amoxicillin
- Where
- 3 sites in Germany
- Volunteers
- 200 people
- Sponsor
- Technische Universität Dresden
Persistent Helicobacter Pylori Infection
Effect of Probiotics on Eradication of Persistent H.Pylori Infection
This study aims to investigate the possible safety and efficacy of probiotics (Bifidobacterium Infants, Enterococcus Feacium, and Lactobacillus Acidophilus) on the eradication rate of Helicobacter pylori and the incidence of…
- Trial name
- NCT05674864
- Testing
- Bifidobacterium Infants plus Enterococcus Feacium plus Lactobacillus Acidophilus
- Where
- Egypt
- Volunteers
- 92 people
- Sponsor
- Tanta University
Helicobacter Pylori Infection
Probiotics in the Reduction of Adverse Effects and Dysbiosis of H. Pylori Eradication
The investigators aimed to assess the effect of probiotic supplementation with Vigiis 101-LAB during H. pylori eradication therapy with 14-day sequential therapy in the reduction of adverse effects and the restoration of the…
- Trial name
- NCT03722433
- Testing
- Vigiis 101-LAB and sequential therapy
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Helicobacter Pylori Infection, Helicobacter Pylori Infection, Susceptibility to
Eradication of H. Pylori Infection With Moxifloxacin
The main objective of the study is to compare the effectiveness of moxifloxacin triple therapy with levofloxacin-based sequential therapy in terms of eradication rate, safety, and patient compliance.
- Trial name
- RCT (NCT05863858)
- Testing
- Sequential Regimen: Levofloxacin 500 mg BID, Amoxicillin 1 gm BID, omeprazole 20 mg BID for first five days followed by Levofloxacin 500 mgBID, Tinidazole 500 mg BID, Omeprazole 20 mg BID, Triple Regimen: Moxifloxacin 400mg OD, Amoxicillin 1 gm BID, Omeprazole 20mgBID
- Where
- Pakistan
- Volunteers
- 162 people
- Sponsor
- Iyad Naeem Muhammad, PhD
Helicobacter Pylori Infection
Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for H. Pylori Infection (TATH-1)
Standard eradication therapies using proton pump inhibitors (PPIs) require double doses to achieve sufficient acid suppression, yet failure rates remain high due to antibiotic resistance.
- Trial name
- TATH-1 (NCT05647278)
- Testing
- Tegoprazan 50 mg, tablets, orally, qd, Esomeprazole 20mg BID, Tegoprazan 50 mg, tablets, orally, bid
- Where
- China
- Volunteers
- 370 people
- Sponsor
- Zhang Xiaofeng,MD
Gut Microbiota, Metabolic Disturbance
The Effects of High-dose Dual Therapy With Probiotics on Gut Microbiota for Helicobacter Pylori Rescue Treatment
The aim of this study was to evaluate the effects of High-dose Dual therapy combined with probiotics on the gut microbiota for Helicobacter pylori rescue treatment.
- Conditions
- Gut Microbiota, Metabolic Disturbance, Helicobacter Pylori Eradication
- Trial name
- NCT06292546
- Testing
- Vonoprazan, Amoxicillin, Bacillus subtilis enteric-coated capsules
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Zhongshan Hospital (Xiamen), Fudan University
Dyspepsia, Chronic Gastritis
Helicobacter Pylori Eradication With Berberine Plus Amoxicillin Triple Therapy Versus Bismuth-containing Quadruple Therapy
This study aims at evaluating efficacy and safety of berberine hydrochloride, amoxicillin and rabeprazole triple therapy versus bismuth-containing quadruple therapy(amoxicillin, clarithromycin, rabeprazole and bismuth) in the…
- Conditions
- Dyspepsia, Chronic Gastritis, Gastric Cancer, Helicobacter Pylori Infection
- Trial name
- NCT04697186
- Testing
- Berberine, Amoxicillin, Rabeprazole
- Where
- China
- Volunteers
- 524 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Gastric Cancer, H Pylori Infection
H. Pylori Screen-and-treat Study in a Population of Young Adults
Gastric cancer remains a major challenge to public health on a global scale. H. pylori related cancer burden contributes to the largest proportion of cancer cases attributable to infections in Europe.
- Conditions
- Gastric Cancer, H Pylori Infection, H Pylori Eradication, H-pylori
- Trial name
- NCT06275204
- Testing
- Bismuth-based quadruple therapy, Levofloxacin-based quadruple therapy, Standard triple therapy
- Where
- 7 sites in Croatia, Ireland and 4 more
- Volunteers
- 6,800 people, healthy volunteers welcome
- Sponsor
- University of Latvia
H Pylori Infection Eradication, Antibiotics Therapeutic Strategies
Therapeutic Trial Comparing Triple Therapy Guided by the PCR Detection of Clarithromycin Resistance vs Empiric Concomitant Quadruple Therapy for Helicobacter Pylori Infection
The H pylori infection remains a public health problem. The eradication rate with the first line triple therapy (PPI-amoxicillin-clarithromycin) is insufficient (estimated at 70%) due to the frequency of resistance to…
- Conditions
- H Pylori Infection Eradication, Antibiotics Therapeutic Strategies, H Pylori Eradication
- Trial name
- Hepysé (NCT02576236)
- Testing
- Quadruple concomitant therapy treatment, Triple therapy guided by the result of the molecular resistance test
- Where
- France
- Volunteers
- 2,500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Gastric Cancer, Helicobacter Pylori Infection
Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General Population
The aim of this study is to define the role of H. pylori eradication in the prevention of gastric cancer and its precursors in the context of a population-based endoscopic screening program.
- Trial name
- HELPER (NCT02112214)
- Testing
- 10-day bismuth-based quadruple therapy
- Where
- 11 sites in South Korea
- Volunteers
- 5,224 people, healthy volunteers welcome
- Sponsor
- National Cancer Center, Korea
Gastrointestinal Ulcer Haemorrhage, Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Helicobacter Eradication Aspirin Trial
HEAT (Helicobacter Eradication Aspirin Trial) is a large simple double-blind placebo controlled outcomes study of Helicobacter pylori (H. pylori) eradication to prevent ulcer bleeding in aspirin users.
- Trial name
- HEAT (NCT01506986)
- Testing
- Lansoprazole 30mg, Clarithromycin 500mg, Metronidazole 400mg
- Where
- 6 sites in United Kingdom
- Volunteers
- 30,024 people
- Sponsor
- University of Nottingham
Helicobacter Pylori Infection
Intraluminal Therapy for Helicobacter Pylori Infection
Helicobacter pylori (H. pylori) is the most common chronic bacterial infection in humans. The prevalence of H. pylori is about 30~50% in the Western adult population.
- Trial name
- NCT03124420
- Testing
- Lansoprazole, Amoxicillin, Clarithromycin
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Mackay Memorial Hospital
Helicobacter Infections
Eradication Rates of Helicobacter Pylori and Its Affecting Factors
The purpose of this study is to investigate the trend of eradication rates of first-line triple therapy for Helicobacter pylori in recent ten years and clinical factors that affect the eradication in Korean.
- Trial name
- NCT01922505
- Testing
- PPI triple therapy
- Where
- South Korea
- Volunteers
- 2,500 people
- Sponsor
- Seoul National University Bundang Hospital
Helicobacter Pylori Infection, Comorbidities and Coexisting Conditions
Real-world Treatment of H. Pylori Eradication in Patients with Comorbidity
Most of the studies of H. pylori eradication were conducted in academic institutes and designed to enrolled patients who did not have comorbidities.
- Conditions
- Helicobacter Pylori Infection, Comorbidities and Coexisting Conditions, Real-world Outcome, Medication Adherence
- Trial name
- Real-world_Hp (NCT05475431)
- Testing
- The sequential therapy, The triple therapy, The hybrid therapy
- Where
- 2 sites in Taiwan
- Volunteers
- 1,053 people
- Sponsor
- National Cheng-Kung University Hospital
Helicobacter Infections, Stomach Neoplasms
Helicobacter Pylori Eradication to Prevent Gastric Cancer
Gastric cancer is the fourth most common type of cancer and the second leading cause of cancer-related death in the world. In China, more than 390,000 new patients are diagnosed with gastric cancer and more than 300,000 patients…
- Trial name
- NCT01133951
- Testing
- OAC triple therapy
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Jie-Jun Wang
HELICOBACTER PYLORI INFECTIONS
Efficacy and Safety of 7-day Triple Therapy Containing Amoxicillin and Tetracycline Versus 14-day Dual Therapy for Helicobacter Pylori Eradication
With the increasing prevalence of antibiotic resistance, the clinical efficacy of conventional 7-day triple therapy for Helicobacter pylori eradication has been substantially diminished.
- Trial name
- PSM (NCT07333001)
- Testing
- 7-day triple therapy, 14-day dual therapy
- Where
- China
- Volunteers
- 508 people
- Sponsor
- Yueyue Li
Gastritis, Dyspepsia
Helicobacter Rescue Therapy With High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy
This study aims at evaluating efficacy and safety of high-dose esomeprazole and amoxicillin dual therapy(esomeprazole and amoxicillin) versus bismuth-containing quadruple Therapy(bismuth，esomeprazole，tetracycline and…
- Conditions
- Gastritis, Dyspepsia, Helicobacter Pylori Infection, Gastric Cancer
- Trial name
- NCT04678492
- Testing
- Esomeprazole, Amoxicillin, Bismuth
- Where
- China
- Volunteers
- 658 people
- Sponsor
- Xijing Hospital of Digestive Diseases
H. Pylori Infection
Oral Helicobacter Pylori Eradication
Helicobacter pylori (H. pylori) is a serious health threat that infects approximately half of the global population. In addition to colonizing the stomach, H.
- Trial name
- NCT06045832
- Testing
- MAXPOWER Biological Antibacterial Liquid, Water
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Changhai Hospital
Helicobacter Pylori Infection
Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole
The purpose of the study is assess whether the various forms of triple regimen of administration of treatment of Helicobacter pylori (before meals (fasting), after meals, and any independent mealtime) influence the rate of…
- Trial name
- NCT02552641
- Testing
- Food effect, Esomeprazole, Amoxicillin
- Where
- Brazil
- Sponsor
- EMS